Investment Committee Sign-Off
The formal approval step where a group separate from the strategy's own researcher reviews the evidence and decides whether a strategy is allowed to trade real capital — and how much.
Before a new strategy is allowed to trade meaningful capital, most funds require it to pass through a formal decision point where people other than its own researcher evaluate the evidence and either approve it, reject it, or send it back for more work. Investment committee sign-off is that gate. Its purpose is structural rather than purely technical: the researcher who built a strategy is naturally invested in seeing it approved, so the decision is deliberately routed through people who have no such stake, reviewing a standardized package of evidence rather than taking the researcher's summary at face value.
A typical sign-off package includes the backtest results, the out-of-sample or walk-forward validation, an account of the strategy's economic rationale, capacity estimates, and — often the most revealing part — a record of what stress tests and red-team checks were already run and what they found. The committee's job is not to re-run the backtest themselves but to probe it: ask what happens in scenarios the backtest didn't cover, question why particular parameter choices were made, and decide whether the evidence presented actually supports the size of allocation being requested. A strategy can pass technical validation and still receive a smaller allocation, or a probationary period with tighter monitoring, if the committee isn't fully convinced.
A concrete example: a strategy with a strong five-year backtest comes to committee requesting a $50 million allocation. In review, a committee member notices the backtest period excludes 2020's volatility spike due to a data availability gap, and asks the researcher to specifically test the strategy's behavior during that period using a different data source. The result shows the strategy would have lost significantly more than its typical drawdown during that stretch. Rather than rejecting the strategy outright, the committee approves a reduced $15 million allocation with an explicit drawdown-based de-risking trigger set tighter than usual, reflecting the added uncertainty the gap revealed.
Investment committee sign-off routes the decision to trade a new strategy through people with no personal stake in its approval, reviewing a standardized evidence package rather than the researcher's own summary — and the outcome can be a smaller allocation or added conditions, not just a binary yes or no.
Further reading
- Prado, Advances in Financial Machine Learning, ch. 11